Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) fell 4.3% on Friday . The company traded as low as $14.24 and last traded at $14.48. 3,310 shares changed hands during trading, a decline of 96% from the average session volume of 78,230 shares. The stock had previously closed at $15.13.
The stock has a fifty day moving average of $12.18 and a two-hundred day moving average of $15.50.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The business had revenue of $27.17 million for the quarter. Equities analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
• Five stocks we like better than Gyre Therapeutics
• Why This AI Stock is Rising Despite Tech Sell-Off
• What is the Nikkei 225 index?
• Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
• What is a buyback in stocks? A comprehensive guide for investors
Receive News & Ratings for Gyre Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gyre Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.…Read more by Defense World Staff
